MARATTO

article · Immunopharmacology and Immunotoxicology

Effect of zinc oxide nanoparticles on circulating neutrophils in carbon tetrachloride (CCl4) induced liver fibrosis in rats

Abstract

OBJECTIVE: (sumac) green-synthesized zinc oxide nanoparticles (ZnO-NPs) on circulating neutrophils and the histological structure of liver in carbon tetrachloride (CCl4) treated rats. RESULTS: CCl4 rats showed biochemical changes and histopathological damage, together with increased neutrophil markers [myeloperoxidase (MPO) and citrullinated histone (H3cit)] as well as decreased neutrophils' phagocytic activity and miR-223 expression compared to control. ZnO-NPs treatment was significantly associated with biochemical and histopathological improvement, decreased neutrophil markers, and increased both phagocytic activity and miR-223 expression. In addition, green-synthesized ZnO-NPs were associated with greater histopathological improvement and a significant increase in miR-223 expression in comparison to chemically prepared ZnO-NPs. CONCLUSIONS: It can be concluded that ZnO-NPs may have immunomodulatory effects on circulating neutrophils that have a biological impact on disease progression. In addition, green-synthesized ZnO-NPs may be more efficient than chemically synthesized ones at providing a greater modulatory effect on circulating neutrophils and better hepatoprotective effects.

Research topics

  • Liver physiology and pathology
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Immune cells in cancer

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/08923973.2026.2673544

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.